Added to YB: 2024-01-25
Pitch date: 2024-01-24
SGMT [bullish]
Sagimet Biosciences Inc.
-60.79%
current return
Author Info
No bio for this author
Company Info
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
Market Cap
$251.7M
Pitch Price
$15.89
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.97
P/E
-4.33
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Sagimet: Additional Upside Possible After Latest NASH Data Release
SGMT: Denifanstat met Phase 2b NASH F2-F3 endpoints, Phase 3 possible in H2 '24 after FDA mtg. Phase 1 liver impairment data due early '24. Partner Ascletis: Ph3 glioblastoma enrolled, +Ph2 acne data. $96M IPO + Series A funded >12mo. Risks: FDA, trial results, FASN strategy.
Read full article (6 min)